Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Conserved protein | 0.1583 | 0.4121 | 0.5 |
Trypanosoma brucei | RNA helicase, putative | 0.0174 | 0.0333 | 1 |
Mycobacterium tuberculosis | Hypothetical protein | 0.1583 | 0.4121 | 0.5 |
Mycobacterium tuberculosis | Long conserved protein | 0.1583 | 0.4121 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.1583 | 0.4121 | 0.5 |
Brugia malayi | Thioredoxin family protein | 0.1583 | 0.4121 | 1 |
Trichomonas vaginalis | peptide N-glycanase, putative | 0.1583 | 0.4121 | 0.5 |
Mycobacterium leprae | Conserved hypothetical protein | 0.1583 | 0.4121 | 0.5 |
Echinococcus granulosus | Transglutaminase | 0.1583 | 0.4121 | 0.5 |
Mycobacterium leprae | Conserved hypothetical protein | 0.1583 | 0.4121 | 0.5 |
Mycobacterium ulcerans | putative transglutaminase-like protein | 0.1583 | 0.4121 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.1583 | 0.4121 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.1583 | 0.4121 | 0.5 |
Giardia lamblia | Transglutaminase/protease, putative | 0.1583 | 0.4121 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.1583 | 0.4121 | 0.5 |
Echinococcus multilocularis | Transglutaminase | 0.1583 | 0.4121 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.1583 | 0.4121 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.1583 | 0.4121 | 0.5 |
Loa Loa (eye worm) | follicle stimulating hormone receptor | 0.0227 | 0.0475 | 0.5 |
Mycobacterium ulcerans | transglutaminase family protein | 0.1583 | 0.4121 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC50 (functional) | > 50 ug ml-1 | Antibacterial activity against Escherichia coli ATCC 35218 after 24 hrs by MTT assay | ChEMBL. | 21856050 |
MIC50 (functional) | > 50 ug ml-1 | Antifungal activity against Escherichia coli ATCC 10231 after 48 hrs by MTT assay | ChEMBL. | 21856050 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.